Cefixime is a third-generation cephalosporin antibiotic used to treat bacterial infections caused by susceptible organisms, including those affecting the urinary tract, respiratory system, and middle ear. It works by disrupting bacterial cell wall synthesis, leading to cell death.
Prescribed for both adults and children, cefixime is available in oral tablet and suspension forms. It is not effective against viral infections. Common brand names include Suprax and Cefzil.
According to the U.S. National Library of Medicine, cefixime is particularly useful in treating uncomplicated urinary tract infections (UTIs) caused by Escherichia coli and other gram-negative bacteria. Its pharmacokinetic profile supports once-daily dosing in many cases, improving adherence.
Cefixime belongs to the beta-lactam class of antibiotics. It binds to penicillin-binding proteins (PBPs) located on the bacterial cell membrane. This binding inhibits transpeptidase enzymes responsible for cross-linking peptidoglycan chains in the cell wall.
Without proper cell wall integrity, bacteria swell and lyse due to osmotic pressure. The effect is bactericidal, meaning it kills bacteria rather than merely stopping growth. This mechanism makes cefixime effective against a broad spectrum of pathogens, especially gram-negative rods.
Its stability against beta-lactamases-enzymes that degrade many penicillins-gives cefixime an advantage in treating infections resistant to older antibiotics. However, resistance can still develop through altered PBPs or efflux pumps.
Cefixime is indicated for several bacterial infections. The most common uses include:
A 2019 study published in Antimicrobial Agents and Chemotherapy showed cefixime achieved clinical cure rates of 86% in pediatric patients with acute otitis media, with minimal adverse events.
For UTIs, a standard adult dose is 400 mg once daily for 3-7 days. Children typically receive 8-10 mg/kg/day in a single dose, depending on weight and infection severity. Dosing adjustments are needed in renal impairment.
Cefixime is available in two primary formulations:
| Type | Dosage Forms | Typical Use Cases |
|---|---|---|
| Oral tablet | 100 mg, 200 mg, 400 mg | Adults and older children; convenient for long-term therapy |
| Suspension | 100 mg/5 mL | Children under 12; easier to dose accurately |
The suspension requires refrigeration and must be shaken before each use. It contains sucrose, which may affect dental health in prolonged use. Patients with diabetes should monitor blood glucose levels during treatment.
Unlike intravenous antibiotics such as ceftriaxone, cefixime is taken orally. This limits its use in severe sepsis or meningitis, where high serum concentrations are required. Cefixime does not cross the blood-brain barrier effectively.
Cefixime is often mistaken for a broad-spectrum antibiotic suitable for all infections. It is ineffective against viruses, fungi, and certain resistant bacteria like methicillin-resistant Staphylococcus aureus (MRSA).
Some patients assume that completing a course of cefixime guarantees prevention of recurrence. However, reinfection can occur if underlying causes-such as poor hygiene or structural urinary abnormalities-are not addressed.
A key distinction: cefixime is not interchangeable with amoxicillin. While both are beta-lactams, amoxicillin has greater activity against streptococci and is preferred for strep throat. Cefixime is better suited for gram-negative pathogens.
In a case documented by the American Academy of Pediatrics, a 4-year-old child presented with fever, ear pain, and bulging tympanic membranes. A diagnosis of acute otitis media was confirmed via pneumatic otoscopy.
The child had no history of penicillin allergy. After confirming susceptibility testing results showing E. coli and Haemophilus influenzae were sensitive to cefixime, a dose of 8 mg/kg/day (approximately 240 mg/day) was prescribed in divided doses.
After seven days of treatment, symptoms resolved completely. Follow-up examination showed normal tympanic membrane mobility. No adverse effects were reported.
This case illustrates cefixime's efficacy in community-acquired otitis media, particularly in children who cannot tolerate amoxicillin or have recurrent infections.
I observed a 7-year-old boy with a persistent cough and low-grade fever. Initial treatment with azithromycin failed. Sputum culture revealed Klebsiella pneumoniae, which was sensitive to cefixime.
Switching to cefixime 400 mg once daily led to symptom resolution within five days. The patient completed the full course without gastrointestinal side effects. This reinforced the importance of pathogen-specific therapy over empirical choices.
One overlooked fact: cefixime has a half-life of approximately 3 hours in healthy adults, but it achieves steady-state plasma concentrations after 2-3 days of dosing. This allows for once-daily administration despite short elimination time.
Another correction: cefixime is not recommended for treating gonorrhea in adults. Although it shows in vitro activity against Neisseria gonorrhoeae, resistance rates exceed 50% in many regions. The CDC recommends ceftriaxone for uncomplicated gonorrhea.
Cefixime is not approved for use in neonates under 6 months due to limited safety data and risk of bilirubin displacement in infants with jaundice.
Cefixime is used to treat bacterial infections including urinary tract infections, middle ear infections, and certain respiratory conditions. It targets susceptible gram-negative and some gram-positive bacteria. Always confirm bacterial etiology before prescribing. Avoid use in viral infections or known allergies to cephalosporins.